Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Luye Looks To Horizons Beyond Pharma, China

Executive Summary

Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.

Advertisement

Related Content

Luye Builds China Cancer Diagnosis Capability Via Vela Investment
Waiver Aids Luye’s US Approval Quest For Risperdal Consta Rival
Luye Pharma of China to raise $763m in upcoming Hong Kong IPO

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel